Journal
BIOCHEMICAL PHARMACOLOGY
Volume 174, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2020.113794
Keywords
Humanized mice; Cytokine humanization; Xenotransplantation; Immunodeficient mouse models; Myeloid malignancy; Pre-clinical studies
Categories
Funding
- American Cancer Society [93-032-16]
- U.S. Department of Defense Peer Reviewed Cancer Research Program Career Development Award [CA120128, W81XWH-12-PRCRP-CDA]
- State of Connecticut Department of Public Health [RFP 2014-0135]
- Frederick Deluca Foundation
- Young Scientists Fund of the National Natural Science Foundation of China [81800122]
- Animal Modeling Core of the Yale Cooperative Center of Excellence in Hematology [NIDDK U54DK106857]
- Yale Hematology Tissue Bank at Yale University School of Medicine
- Yale Comprehensive Cancer Center
- Edward P. Evans Foundation
Ask authors/readers for more resources
Humanized mice have proven to be invaluable for human hematological translational research since they offer essential tools to dissect disease biology and to bridge the gap between pre-clinical testing of novel therapeutics and their clinical applications. Many efforts have been placed to advance and optimize humanized mice to support the engraftment, differentiation, and maintenance of hematopoietic stem cells (HSCs) and the human hematological system in order to broaden the scope of applications of such models. This review covers the background of humanized mice, how they are used as platforms to model myeloid malignancies, and the various current and potential approaches to further enhance their utilization in biomedical research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
